Allurion Technologies' Virtual Care Suite (VCS) is now available to license in the United States for providers offering GLP-1 and other anti-obesity medication therapy, bariatric surgery, and weight loss devices. The company describes the VCS as a weight-loss management suite powered by artificial intelligence (AI) featuring remote patient monitoring, telehealth and care team collaboration.
U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday. The Dow traded down 0.59% to 38,894.58 while the NASDAQ fell 0.10% to 16,261.88. The S&P 500 also fell, dropping, 0.28% to 5,197.03.
Equities Research Analysts’ new coverage for Thursday, April 4th: StockNews.com started coverage on shares of ARCA biopharma (NASDAQ:ABIO). The firm issued a sell rating on the stock. StockNews.com began coverage on shares of Acorda Therapeutics (NASDAQ:ACOR). The firm issued a buy rating on the stock. StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD). They […]
Allurion Technologies, Inc. , a company dedicated to ending obesity, today announced that it will be participating in the 34th Annual Oppenheimer Healthcare MedTech & Services Conference, taking.